Drugs / C31G
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials · 1 met primary · 2 missed | ||||||
| Phase 3 | NCT00130078 | Sep 2004 → ? | HIV infectious disease | Biosyn | Unknown | Missed primary |
| Phase 3 | NCT00274261 | Jun 2004 → Jul 2008 | pregnancy disorder | Premier Research | Completed | Met primary |
| Phase 3 | NCT00129532 | Jan 2004 → ? | HIV infectious disease | Biosyn | Unknown | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT03119831 | Nov 2015 → Jul 2016 | periodontitis | National and Kapodistrian University of Athens | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C31G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00130078 ↗ |
| Known as | SAVVY | “The objective of this trial was to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female vaginal transmission of HIV infection among women at high risk.” PMID 18213382 ↗ Jan 20081“1.0% C31G (SAVVY) vaginal gel” NCT00129532 ↗ |
| Route | Other | “The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study” NCT00274261 ↗ |